GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice
A novel drug candidate outperforms current obesity treatments in early testing, pointing toward potentially more powerful options beyond today's available medications.
Researchers at Helmholtz Munich developed a first-in-class unimolecular quintuple agonist (GLP-1-GIP-lanifibranor) that merges incretin receptor co-agonism with targeted PPARα/γ/δ activation in GLP-1R/GIPR-expressing cells, achieving superior anti-obesity and anti-diabetic effects compared to semaglutide in preclinical models. Published in Nature, this approach represents a conceptually novel next-generation pharmacology beyond current GLP-1/GIP dual agonism, though efficacy in humans remains unproven.
What the study was
- Study design
- Preclinical animal study (obese/insulin-resistant mice); in vitro mechanistic validation
- Population
- Obese and insulin-resistant mouse models (DIO, double incretin receptor knockout)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Nature
Why it surfaced
First unimolecular quintuple agonist published in Nature; outperforms semaglutide in preclinical models; conceptually novel combination of incretin + PPAR biology. Triage score capped at 5 per non-human study rule, but NOVEL_TREATMENT flag elevates to HIGH pipeline priority.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.